Kestra Medical Technologies makes and sells the ASSURE WCD (wearable cardioverter defibrillator), a wearable medical device that protects patients at elevated risk of sudden cardiac arrest. The device is worn under regular clothing, continuously monitors heart rhythm, and automatically delivers a defibrillation shock if it detects a life-threatening arrhythmia. WCDs are typically prescribed as a temporary bridge for patients who recently suffered a heart attack or were diagnosed with heart failure, while doctors monitor whether the patient's condition warrants a permanent implanted device. Kestra does not sell the ASSURE WCD outright — it leases the device and bills insurance payors directly, primarily Medicare, Medicaid, and commercial insurers. Revenue is driven by the number of active prescriptions and the average prescription length, currently around 3.4 months. A key feature of the model is device reuse: each physical device serves roughly three patients per year, so incremental costs decline as patient volume scales. Kestra's roughly 80-person direct sales force targets cardiologists and electrophysiologists, while a contracted network of over 300 patient specialists handles device fitting and training. Kestra supports this model with 15+ regional warehouses enabling 24-hour U.S. delivery, and in-house revenue cycle management for payor billing. Kestra remains pre-profitability. Beyond its core WCD business, Kestra has a wearable ECG product for post-WCD cardiac monitoring, and plans to pursue international expansion into Europe.